At the end of this activity, participants should be able to:
1. Synthesize contemporary data into endovascular device selection and decision making for SFA and BTK interventions.
2. Review new clinical trial data in both SFA and BTK territories which have changed practice.
3. Assess unmet needs and new solutions in interventional techniques to enhance outcomes.
4. Discuss the next generation of investigational technologies currently being evaluated for SFA and BTK/CLTI interventions.
Individuals in control of content reported the following relevant financial relationships with ineligible companiesduring the content development process for this activity. All relevant financial relationships were mitigated beforethe start of the activity. Planner Jay S. Mathews: Consulting and PI with Abbott. Advisory Board, Consulting, PI, and Speaker Bureau with Boston Scientific Corp. Advisory Board, Consulting, and PI with Medtronic. Advisory Board, Consulting, PI, and Speaker Bureau with Philips. Advisory Board, Consulting, PI, and Speaker Bureau with Reflow Medical. Advisory Board, Consulting, PI, and Speaker Bureau with Cordis. Advisory Board and PI with Akura Medical. Advisory Board, Consulting, PI, and Speaker Bureau with Innova Medical. Advisory Board with Protexa. Advisory Board, Consulting, PI, and Speaker Bureau with Cagent.
Faculty Jun Li: Consulting with Abbott. Consulting with Medtronic. Consulting with Boston Scientific Corp.
Hady Lichaa: Consulting and Speaker Bureau with Surmodics. Consulting and Speaker Bureau with Abbott. Speaker Bureau with Medtronic.
Jay Mohan: No financial relationships with ineligible companies.
Peter Monteleone: Advisory Board and Consulting with Boston Scientific Corp. Advisory Board and Consulting with Medtronic.
Zola M. N'Dandu: Consulting with Abbott. Consulting with Boston Scientific Corp. Consulting with W.L. Gore and Associates, Inc. PI with LimFlow. Consulting and Speaker Bureau with BD. Advisory Board with Provisio. Consulting with Inari.
Sahil A. Parikh: Advisory Board and PI with Abbott. Advisory Board and PI with Boston Scientific Corp. Advisory Board with Medtronic. Advisory Board and PI with Philips. PI with Concept Medical. Consulting with Terumo. Consulting with Stryker. Advisory Board with Cordis. PI with Reflow Medical. Consulting with Penumbra. Has stock options in a private or public company with Encompass Vascular. Has stock options in a private or public company with Advanced Nanotherapies. Advisory Board, Consulting, and PI with J&J Medtech. Speaker Bureau with Recor Medical. PI with Akura Medical.
Thuy Pham Ryan: Advisory Board, Consulting, and Speaker Bureau with Philips. Consulting and Speaker Bureau with Shockwave.
Maya Serhal: No financial relationships with ineligible companies.
Anish J. Thomas: No financial relationships with ineligible companies. Reviewers Andrew Klein: No relevant financial relationships with ineligible companies.
SCAI Staff Robert Bartel and Laura Porter: No relevant financial relationships with ineligible companies.
Accreditation StatementThe Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit DesignationSCAI designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.5 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful CompletionWatch the content and complete the evaluation to obtain credit.
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company.
SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.